What question did this study set out to answer?

To compare the efficacy and safety of sequential intravenous-to-oral ciprofloxacin versus intravenous ceftazidime plus tobramycin in hospitalized pediatric cystic fibrosis patients experiencing acute pulmonary exacerbations associated with Pseudomonas aeruginosa.

January 1, 1997The Pediatric Infectious Disease Journal

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations

View Full Paper

Ask AI

Bookmark

Authors

DCDeborah ChurchBayer (United States)JKJAMSHED F. KANGA RKRobert J. KuhnUniversity of Kentucky HealthCare

Discussion

Member takes

Implication

Randomized double-blind trial shows sequential intravenous and oral ciprofloxacin matches standard therapy in pediatric cystic fibrosis exacerbations, indicating an effective alternative regimen.

Key Points

To compare the efficacy and safety of sequential intravenous-to-oral ciprofloxacin versus intravenous ceftazidime plus tobramycin in hospitalized pediatric cystic fibrosis patients experiencing acute pulmonary exacerbations associated with Pseudomonas aeruginosa.
Conducted a prospective, randomized, double-blind trial involving 130 hospitalized pediatric cystic fibrosis patients aged 5 to 17 years.
Patients received either intravenous ciprofloxacin (10 mg/kg every 8 hours for 7 days) followed by oral ciprofloxacin (20 mg/kg every 12 hours for ≥3 days), or intravenous ceftazidime (50 mg/kg every 8 hours) plus intravenous tobramycin (3 mg/kg every 8 hours) for ≥10 days.
Clinical progress, bacteriologic status, and safety profiles were monitored throughout the treatment period and during a 2- to 4-week follow-up.
All 84 evaluable patients across both arms experienced clinical improvement, with relapses occurring in 3 patients receiving ciprofloxacin compared to 2 patients receiving ceftazidime/tobramycin at 2- to 4-week follow-up.
Treatment-associated musculoskeletal adverse events occurred in 22% of ciprofloxacin-treated patients versus 21% of ceftazidime/tobramycin-treated patients (n = 129), with none requiring study drug discontinuation.
Clinical recovery correlated directly with improvement in pulmonary function and clinical scores, but did not correlate with bacteriologic eradication of Pseudomonas aeruginosa.

Cite This Study

Church et al. (1997) studied this question.

synapsesocial.com/papers/6a894e9ae0083a7c2c4323d6 https://doi.org/10.1097/00006454-199701000-00031

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial shows sequential intravenous and oral ciprofloxacin matches standard therapy in pediatric cystic fibrosis exacerbations, indicating an effective alternative regimen.

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations

Discussion

Member takes

Implication

Key Points

Cite This Study

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider